

**Freedom of Information Act 2000 - Request Reference FoI/21/063**

**Biologic Drugs**

**Request Details**

**Q1. Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:**

- Adalimumab – Humira 0
- Adalimumab Biosimilar 0
- Apremilast 15 (*data includes 3 months from hospital dispensing but only 2 months from prescriptions dispensed in the community (December data has not been uploaded yet)*)
- Brodalumab - 0
- Certolizumab - 0
- Dimethyl fumarate - 1
- Etanercept – Enbrel - 0
- Etanercept Biosimilar - 0
- Guselkumab - 0
- Infliximab – Remicade - 0
- Infliximab Biosimilar - 1
- Ixekizumab - 0
- Risankizumab - 0
- Secukinumab - 0
- Tildrakizumab - 0
- Ustekinumab - 0

**Q2. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:**

- Adalimumab – Humira - 0
- Adalimumab Biosimilar - 9
- Golimumab - 0
- Infliximab – Remicade - 0
- Infliximab Biosimilar - 103
- Tofacitinib - 2
- Ustekinumab - 21
- Vedolizumab - 146

**Q3. If possible, could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department for Ulcerative Colitis ONLY with the following biologic drugs:**

· Adalimumab – Humira	0
· Adalimumab Biosimilar	Amgevita 47
· Golimumab	1
· Infliximab – Remicade	0 (do not use)
· Infliximab Biosimilar	34
· Tofacitinib	10
· Ustekinumab	3
· Vedolizumab	75